Skip to content
CancerIndex

Publication

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

Authors not recorded

N Engl J Med2012PMID 22187960stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

Curated evidence

Evidence citing this paper (17)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
22187960
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–17 of 17 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
DICER1 D1709G2
(oncogenic)Granulosa Cell TumorOncogenicCSupports Oncogenicity1accepted
EID5897

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with one mutation in a Juvenile ovarian granulosa-cell tumor (1/14; 7%). This individual had a somat… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
(predisposing)Ovarian Sertoli-Leydig Cell TumorALIASPredisposingCSupports Predisposition3accepted
EID5887

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1709G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 E1813 mutations1
(diagnostic)Malignant Ovarian NeoplasmDiagnosticBSupports Positive5rejected
EID7049

E1813 residue has been described as a hotspot for somatic missense mutations in DICER1.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 D1810Y2
(oncogenic)Mature Ovarian TeratomaALIASOncogenicCSupports Oncogenicity1submitted
EID5901

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). Of the eight mature teratomas that were evaluated, one had a somatic mutation in D1810Y.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
〃Ovarian Sertoli-Leydig Cell TumorALIASOncogenicCSupports Oncogenicity1submitted
EID5890

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%).Two Sertoli-Lydig cell tumors harbo… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 D1709E2
(predisposing)Ovarian Sertoli-Leydig Cell TumorALIASPredisposingCSupports Predisposition2accepted
EID5888

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
(oncogenic)Glandular Pattern Ovarian Yolk Sac TumorUNRESOLVEDOncogenicCSupports Oncogenicity1accepted
EID5900

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a somatic mutation in D1709E.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 D1709N2
(predisposing)Ovarian Sertoli-Leydig Cell TumorALIASPredisposingBSupports Predisposition3accepted
EID5886

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
(oncogenic)Glandular Pattern Ovarian Yolk Sac TumorUNRESOLVEDOncogenicCSupports Oncogenicity1accepted
EID5899

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a somatic mutation in D1709N.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 D1810H1
(predisposing)Ovarian Sertoli-Leydig Cell TumorALIASPredisposingCSupports Predisposition2submitted
EID5889

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810H.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 D1810N1
(oncogenic)Ovarian Sertoli-Leydig Cell TumorALIASOncogenicCSupports Oncogenicity1submitted
EID5891

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810N.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 E1705K1
(predisposing)Ovarian Sertoli-Leydig Cell TumorALIASPredisposingBSupports Predisposition3submitted
EID5885

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were five mutations in E1705… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 E1813G1
(oncogenic)Ovarian Sertoli-Leydig Cell TumorALIASOncogenicCSupports Oncogenicity1submitted
EID5893

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in E1813G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 E1813K1
(oncogenic)Ovarian Sertoli-Leydig Cell TumorALIASOncogenicCSupports Oncogenicity1submitted
EID5894

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in E1813K.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 E1813Q1
(oncogenic)Ovarian Sertoli-Leydig Cell TumorALIASOncogenicCSupports Oncogenicity1accepted
EID5892

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two patients with E1813… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
DICER1 RNase IIIb Mutation2
(diagnostic)Ovarian Sertoli-Leydig Cell TumorALIASDiagnosticBSupports Positive4submitted
EID13129

A sequencing analysis of the DICER1 RNase IIIb region in nonepithelial ovarian neoplasms revealed a striking concentration of somatic mutations at residues required for metal binding within the cataly… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic
(oncogenic)Ovarian Sertoli-Leydig Cell TumorALIASOncogenicDSupports Oncogenicity4submitted
EID13130

Somatic missense alterations repeatedly affecting the metal-coordinating residues of the DICER1 RNase IIIb domain, particularly E1705, D1709, D1810, and E1813, were found across nonepithelial ovarian … (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

civic